JP7054368B2 - Radioactive drug administration system - Google Patents

Description

The present invention relates to a radiopharmaceutical administration system.

Conventionally, the radiopharmaceutical administration device described in Patent Document 1 below is known as a technique in this field. In this device, a transport line for transporting the transport liquid connects the transport liquid syringe and the winged needle. A drug line for supplying radioactive drugs joins this transportation line. A desired amount of radiopharmaceutical is delivered from the drug syringe through the drug line to the transport line and then extruded with the transport fluid by the transport fluid syringe to administer the radiopharmaceutical to the patient through the transport line and winged needle. Will be done.

Japanese Unexamined Patent Publication No. 2008-136786

As described above, the radiopharmaceutical administration device is adapted to administer the radiopharmaceutical in a desired amount of radioactivity. Such a radioactive drug administration device is provided with a shielding function for shielding radiation by covering the internal structure for handling the radioactive drug with a shielding wall or the like. Here, the efforts for radiation safety differ depending on the facility that handles the radiopharmaceutical administration device. Therefore, in facilities where the safety is set higher, it may be required to additionally attach a shielding material to the drug administration device. However, when adding a shielding material to a drug administration device, a regulatory application is required, so it may take time and cost to evaluate safety (evaluation of strength, etc.) and prepare application documents due to the addition of the shielding material. be.

In view of such problems, it is an object of the present invention to provide a radiopharmaceutical administration system capable of easily enhancing the shielding function.

The radiopharmaceutical administration system of the present invention houses a radiopharmaceutical inside a shielding wall, and is arranged so as to surround the outside of the radiopharmaceutical administration device for administering the radiopharmaceutical and the radiopharmaceutical administration device to shield the radiation. A frame portion to which a shielding member can be attached and a shielding member attached to the frame portion are provided.

The radioactive drug administration system of the present invention is arranged so as to surround the outside of the radioactive drug administration device, and includes a frame portion to which a shielding member for shielding radiation can be attached, and a shielding member attached to the frame portion. In such a configuration, the shielding function against radiation can be enhanced only by attaching the shielding member to the frame portion. In addition, since it is not necessary to change the shielding wall itself of the radioactive drug administration device, the shielding function can be enhanced without filing a regulatory application. As described above, the shielding function of the radioactive drug administration system can be easily enhanced.

Further, the frame portion may be capable of attaching a shielding member to any position. In this case, it is possible to enhance the shielding function of the required part according to the safety standards and usage conditions of the facility of the radioactive drug administration system.

Further, the frame portion may be configured so as to be close to and separated from the radioactive drug administration device. In this case, the shielding member can be attached to the frame portion in a state where the frame portion is separated from the radioactive drug administration device.

Further, the frame portion may be provided with wheels. In this case, with a simple configuration, the frame portion can be brought close to and separated from the radioactive drug administration device.

According to the present invention, it is possible to provide a radiopharmaceutical administration system capable of easily enhancing the shielding function.

It is a perspective view which shows the structure of the radiopharmaceutical administration system which concerns on embodiment of this invention. FIG. 3 is a developed perspective view in which the frame portion and the shielding member of the radioactive drug administration system shown in FIG. 1 are separated from the radioactive drug administration device. It is a figure which shows typically the radioactive drug administration apparatus. It is a front view of the radiopharmaceutical administration system which shows an example of the mounting mode of a shielding member. It is a side view of the radiopharmaceutical administration system shown in FIG. It is a side view of the radiopharmaceutical administration system shown in FIG. It is a top view of the radiopharmaceutical administration system shown in FIG.

Hereinafter, embodiments of the present invention will be described with reference to the drawings.

The radiopharmaceutical administration system 100 is a system for administering a radiopharmaceutical to a subject (administration destination) undergoing a PET (positron emission tomography) examination. As shown in FIGS. 1 and 2, the radiopharmaceutical administration system 100 includes a radiopharmaceutical administration device 1, a frame portion 50, and shielding members 61, 62, 63, 64, 65.

The radiopharmaceutical administration device 1 is a device for administering a radiopharmaceutical to a subject. The radiopharmaceutical administration device 1 houses the radiopharmaceutical and various components for administration with the radiopharmaceutical inside the shielding wall 2. The shielding wall 2 constitutes a box-shaped housing having an internal space. The shielding wall 2 constitutes a rectangular parallelepiped housing having a longitudinal direction in the vertical direction, but the shape is not particularly limited. The radiopharmaceutical administration device 1 has a front surface 1a, a back surface 1b, an upper surface 1c, a bottom surface 1d, and side surfaces 1e and 1f. The radioactive drug administration device 1 has a wheel 71 on the bottom surface 1d. In the following description, the direction perpendicular to the front surface 1a and the back surface 1b may be referred to as a front-rear direction, and the direction perpendicular to the side surfaces 1e and 1f may be referred to as a lateral direction. Further, the words "left" and "right" are used with reference to the state when the back surface 1b is viewed from the front surface 1a. Therefore, the side surface 1e is the left side surface, and the side surface 1f is the right side surface.

Here, with reference to FIG. 3, the internal configuration of the radiopharmaceutical administration device 1 will be described in detail. As shown in FIG. 3, the radiopharmaceutical administration device 1 includes a drug vial 3 for accommodating the radiopharmaceutical R and a drug syringe 5 for inhaling the radiopharmaceutical R from the drug vial 3 and discharging the inhaled radiopharmaceutical R. I have. Further, the radiopharmaceutical administration device 1 includes a raw food pack 7 for accommodating the physiological saline (transport liquid) Q, and a raw food syringe 9 (a raw food syringe 9 for sucking the physiological saline Q from the saline pack 7 and discharging the inhaled physiological saline Q). It is equipped with a transport liquid syringe).

The radiopharmaceutical administration device 1 includes a raw food inhalation line 13 that connects the raw food pack 7 and the raw food syringe 9, and a transportation line 15 that connects the raw food syringe 9 and the winged needle 11 (administration unit). The raw food inhalation line 13 and the transport line 15 may partially overlap in the vicinity of the entrance / exit of the raw food syringe 9. The raw food inhalation line 13 includes a collection needle 13a to be inserted into the raw food pack 7. Further, the radioactive drug administration device 1 includes a drug inhalation line 17 that connects the drug vial 3 and the drug syringe 5, and a drug line 19 that connects the drug syringe 5 and the transport line 15. The drug line 19 joins the transport line 15 at the confluence 21 between the raw food syringe 9 and the winged needle 11. The drug inhalation line 17 and the drug line 19 may partially overlap in the vicinity of the entrance / exit of the drug syringe 5. The drug inhalation line 17 includes a collection needle 17a inserted into the drug vial 3.

Further, the radioactive drug administration device 1 includes a waste liquid line 27 branched from the transport line 15 at the branch portion 23 between the merging portion 21 and the winged needle 11. The end of the waste liquid line 27 is connected to the waste liquid bottle 10. A waste liquid buffer 28 is also provided in the middle of the waste liquid line 27. Hereinafter, of the transport line 15, the portion from the raw food syringe 9 to the confluence 21 is the transport line upstream portion 15a, the portion from the confluence 21 to the branch portion 23 is the transport line middle flow portion 15b, and the portion from the branch portion 23 to the winged needle 11 The part up to is called the downstream part 15c of the transportation line.

A measurement unit 31 for measuring the amount of radioactivity of the radioactive drug R inhaled into the drug syringe 5 is provided around the drug syringe 5. Further, a pinch valve 33 that can be opened and closed is provided on the downstream portion 15c of the transport line, and a pinch valve 35 that can be opened and closed is provided on the waste liquid line 27. Further, a passage sensor 37 for detecting the passage of the radioactive agent R is provided on the downstream portion 15c of the transport line. A filter 39 is provided at a position immediately upstream of the winged needle 11 on the downstream portion 15c of the transport line. Further, the radioactive drug administration device 1 has a shielding chamber 43 for accommodating the drug vial 3, a shielding chamber 45 for accommodating the drug syringe 5, and a shielding chamber for accommodating the waste liquid bottle 10 in order to shield the radiation from the radioactive agent R. It is equipped with 47.

Further, the radioactive drug administration device 1 includes a control unit 41 that drives the pistons of the drug syringe 5 and the raw food syringe 9 and controls the inhalation and discharge of the liquid by the drug syringe 5 and the raw food syringe 9. The control unit 41 further controls the opening / closing operation of the pinch valves 33 and 35.

Each line (raw food inhalation line 13, transport line 15, drug inhalation line 17, drug line 19, etc.) is formed of, for example, a tube such as a sterilized extension tube. Further, for example, official materials such as T-shaped pipes are appropriately inserted into the connecting portions and branching portions of the above lines.

Among the above-mentioned components, components other than the filter 39, the winged needle 11, and the line connecting them are housed inside the shielding wall 2. The filter 39, the winged needle 11 and the line connecting them are drawn out of the shielding wall 2.

In the radiopharmaceutical administration device 1, the winged needle 11 is inserted into the subject. After that, when the piston of the drug syringe 5 is pulled down, the radioactive drug R of the drug vial 3 is sucked into the drug syringe 5 through the drug inhalation line 17. Then, with the pinch valve 33 closed and the pinch valve 35 open, the piston of the drug syringe 5 is pushed up. As a result, the radioactive drug R is pushed from the drug syringe 5 into the transport line 15 through the drug line 19. At this time, the excess physiological saline Q in the transport line 15 is discharged to the waste liquid bottle 10 through the waste liquid line 27. By this operation, a part of the physiological saline Q on the transport line 15 is replaced with the radiopharmaceutical R. After that, when the piston of the raw food syringe 9 is pulled down, the physiological saline Q of the raw food pack 7 is sucked into the raw food syringe 9 through the raw food suction line 13. After that, the piston of the raw food syringe 9 is pushed up with the pinch valve 33 opened and the pinch valve 35 closed. As a result, the radiopharmaceutical R in the transport line 15 is administered into the body of the subject together with the saline solution Q through the winged needle 11 by the pressure from the raw food syringe 9.

Returning to FIGS. 1 and 2, the frame portion 50 is arranged so as to surround the outside of the radioactive drug administration device 1, and the shielding members 61, 62, 63, 64, 65 that shield the radiation can be attached. The state of surrounding the outside of the radiopharmaceutical administration device 1 is not only a state in which the frame portion 50 surrounds the radiopharmaceutical administration device 1 over the entire circumference, but also surrounds a part of the radiopharmaceutical administration device 1 in the circumferential direction. It also includes a state that does not surround other parts. In the present embodiment, the frame portion 50 surrounds the radiopharmaceutical administration device 1 at the locations corresponding to the front surface 1a and the side surfaces 1e and 1f, but does not enclose the radiopharmaceutical administration device 1 at the locations corresponding to the back surface 1b. The frame portion 50 includes members 51, 52, 53 constituting the upper frame, members 54, 55, 56 constituting the lower frame, and members 57, 58 connecting the upper and lower frames. As the material of each member 51 to 58, iron, lead, aluminum and the like are adopted.

The members 51, 52, and 53 constituting the upper frame are arranged at a height position near the upper surface 1c of the radiopharmaceutical administration device 1. In a state where the frame portion 50 surrounds the outside of the radioactive drug administration device 1, the member 51 extends laterally so as to face the front surface 1a (or a virtual surface in which the front surface 1a is expanded upward). The members 52 and 53 extend in the front-rear direction so as to face the side surfaces 1e and 1f (or a virtual surface obtained by expanding the side surfaces 1e and 1f upward). The member 51 is arranged so as to connect the front end portions of the members 52 and 53 to each other. No member is provided between the rear ends of the members 52 and 53. As a result, the upper frame has a U-shaped shape such that the rear end side is open.

The members 54, 55, 56 constituting the lower frame are arranged at a height position near the bottom surface 1d of the radiopharmaceutical administration device 1. In a state where the frame portion 50 covers the periphery of the radioactive drug administration device 1, the member 54 extends laterally so as to face the front surface 1a (or a virtual surface in which the front surface 1a is extended downward). The members 55 and 56 extend in the front-rear direction so as to face the side surfaces 1e and 1f (or a virtual surface obtained by extending the side surfaces 1e and 1f downward). The member 54 is arranged so as to connect the front end portions of the members 55 and 56 to each other. No member is provided between the rear ends of the members 55, 56. As a result, the lower frame has a U-shaped shape such that the rear end side is open.

The members 57 and 58 extend in the vertical direction so as to connect the upper frame and the lower frame. The member 57 connects the member 52 on the left side and the member 55. The member 57 is arranged at a substantially central position of the members 52 and 55 in the front-rear direction. The member 58 connects the member 53 on the right side and the member 56. The member 58 is arranged at a substantially central position of the members 53 and 56 in the front-rear direction.

The frame portion 50 is configured so as to be close to and separated from the radioactive drug administration device 1. As shown in FIG. 1, the frame portion 50 can be arranged at a position close to the radiopharmaceutical administration device 1 so as to surround the outside of the radiopharmaceutical administration device 1. Further, as shown in FIG. 2, the frame portion 50 can be arranged at a position separated from the radioactive drug administration device 1. Further, the frame portion 50 can reciprocate between the position shown in FIG. 1 and the position shown in FIG. Specifically, the frame portion 50 includes wheels 59. The wheels 59 are provided at both ends of the member 55 in the front-rear direction and at both ends of the member 56 in the front-rear direction. When the frame portion 50 is moved from the state shown in FIG. 2 to the state shown in FIG. 1, the radiopharmaceutical administration device 1 is brought closer to the radiopharmaceutical administration device 1 from the open rear end side of the upper frame and the lower frame. As a result, the frame portion 50 is arranged so as to surround the outside of the radiopharmaceutical administration device 1 without interfering with the radiopharmaceutical administration device 1.

The shielding members 61, 62, 63, 64, 65 are members that shield radiation. The shielding members 61, 62, 63, 64, 65 are arranged outside the shielding wall 2 as an additional shielding material for the shielding wall 2 of the radioactive drug administration device 1. The shielding members 61, 62, 63, 64, 65 are configured as rectangular plate-shaped members. As the material of the shielding member 61, 62, 63, 64, 65, a material that blocks radiation is adopted, and for example, lead, tungsten, or the like is adopted. The thickness of the shielding member 61, 62, 63, 64, 65 is not particularly limited, but it is preferably set in the range of, for example, 3 to 15 mm so as to ensure the shielding property and not to make the weight excessively heavy. The separation distance between the shielding members 61, 62, 63, 64, 65 and each surface of the radioactive drug administration device 1 is not particularly limited and is determined by the positional relationship with the frame portion 50, but blocks radiation without leakage. Therefore, it is preferably set within 50 mm.

The shielding members 61, 62, 63, 64, 65 are attached to the frame portion 50. The shielding members 61, 62, 63, 64, 65 are detachably attached to the frame portion 50. The method of attaching the shielding members 61, 62, 63, 64, 65 to the frame portion 50 is not particularly limited, but may be attached to the frame portion 50 by, for example, bolting. In addition, the frame portion 50 may have a clamping mechanism for sandwiching and fixing the shielding members 61, 62, 63, 64, 65, and the shielding members 61, 62, 63, 64, 65 may be fitted. It may have a fitting structure for fixing.

The timing at which the shielding members 61, 62, 63, 64, 65 are attached to the frame portion 50 is not particularly limited. The shielding members 61, 62, 63, 64, 65 may be attached to the frame portion 50 when the frame portion 50 is arranged at a position away from the radioactive drug administration device 1 (position shown in FIG. 2). .. Alternatively, the shielding members 61, 62, 63, 64 may be attached to the frame portion 50 when the frame portion 50 is arranged at a position close to the radioactive drug administration device 1 (position shown in FIG. 1). .. The shielding member 65 is attached to the frame portion 50 after the movement so as not to interfere with the radioactive drug administration device 1 when the frame portion 50 is moved so as to be close to the radioactive drug administration device 1.

The shielding member 61 is arranged so as to face the front surface 1a of the radioactive drug administration device 1 and cover the front surface 1a. The shielding member 61 functions as an additional shielding material for the shielding wall 2 on the front surface 1a side. The shielding member 61 is supported by at least one of the front ends of the members 52, 53, 55, 56 of the frame portion 50 and the members 51, 54.

The shielding member 65 is arranged so as to face the back surface 1b of the radioactive drug administration device 1 and cover the back surface 1b. The shielding member 65 functions as an additional shielding material for the shielding wall 2 on the back surface 1b side. The shielding member 65 is supported by at least one of the rear ends of the members 52, 53, 55, 56 of the frame portion 50.

The shielding member 62 is arranged so as to face the upper surface 1c of the radioactive drug administration device 1 and cover the upper surface 1c. The shielding member 62 functions as an additional shielding material for the shielding wall 2 on the upper surface 1c side. The shielding member 62 is supported by at least one of the members 51, 52, and 53 of the frame portion 50.

The shielding member 63 is arranged so as to face the left side surface 1e of the radioactive drug administration device 1 and cover the side surface 1e. The shielding member 63 functions as an additional shielding material for the shielding wall 2 on the side surface 1e side. The shielding member 63 is supported by at least one of the left ends of the members 51 and 54 of the frame portion 50 and the members 52, 55 and 57.

The shielding member 64 is arranged so as to face the right side surface 1f of the radioactive drug administration device 1 and cover the side surface 1f. The shielding member 64 functions as an additional shielding material for the shielding wall 2 on the side surface 1f side. The shielding member 64 is supported by at least one of the right ends of the members 51 and 54 of the frame portion 50 and the members 53, 56 and 58.

A shielding member can be attached to the frame portion 50 at any position. In the example shown in FIG. 1, the shielding members 61, 62, 63, 64, 65 are all attached to the frame portion 50, but at least one of the shielding members 61, 62, 63, 64, 65 is the frame portion 50. It suffices if it is attached to. That is, any one of the front surface 1a, the back surface 1b, the upper surface 1c, the side surface 1e, and 1f of the radioactive drug administration device 1 may be covered with the shielding member, and the other surface may not be covered with the shielding member. Further, in the example shown in FIG. 1, the frame portion 50 can cover substantially the entire surface of the front surface 1a, the back surface 1b, the upper surface 1c, and the side surfaces 1e and 1f, so that the shielding members 61, 62, 63, 64, 65 can be covered. However, the shielding members 61, 62, 63, 64, 65 may be attached so as to cover only a part of each surface. For example, although the shielding members 61, 62, 63, 64, and 65 are each configured as one plate-shaped member, they may be configured as a plurality of divided plate-shaped members. Then, only a part of the divided plate-shaped member may be attached to the frame portion 50.

An example in which a shielding member is attached to an arbitrary portion of the frame portion 50 will be described with reference to FIGS. 4 to 7. However, the configurations shown in FIGS. 4 to 7 are only examples, and the mode of attaching the shielding member to the frame portion 50 may be appropriately changed according to the required shielding performance and the like. As shown in FIGS. 4 to 7, a shielding member 61 covering the front surface 1a, shielding members 63 and 64 covering the side surfaces 1e and 1f, and a shielding member 62 covering the upper surface 1c are attached to the frame portion 50. ing. Further, the shielding members 61, 63, 64, 62 are attached to the frame portion 50 so as to partially cover the necessary portions of the front surface 1a, the side surface 1e, 1f and the upper surface 1c.

The radioactive drug administration device 1 has a door member 76 in the upper region on the front surface 1a side (see FIG. 4). The door member 76 constitutes a door for accessing the internal space of the shielding wall 2 by opening both front surfaces 1a. The administrator who administers the radiopharmaceutical drug sets the radiopharmaceutical or the like in the internal space of the radiopharmaceutical administration device 1 by opening the door member 76. An operation panel 72 is provided on the upper surface 1c of the radioactive drug administration device 1, and a winged needle 11 (see FIG. 7) is pulled out from the upper surface 1c.

The shielding member 61 covers a position of the front surface 1a corresponding to the upper region where the door member 76 is provided (see FIG. 4). Therefore, the lower region of the front surface 1a is exposed without being covered by the shielding member 61. The shielding member 63 is a region of the side surface 1e on the front side of the member 57 and covers a position corresponding to the region on the upper side (see FIG. 5). Therefore, the other region of the side surface 1e is exposed without being covered by the shielding member 63. The shielding member 64 is a region of the side surface 1f on the front side of the member 58 and covers a position corresponding to the region on the upper side (see FIG. 6). Therefore, the other region of the side surface 1f is exposed without being covered by the shielding member 64. The shielding member 62 covers a position of the upper surface 1c corresponding to the vicinity of the center position in the front region (see FIG. 7). Therefore, the other region of the upper surface 1c is exposed without being covered by the shielding member 62. Of the upper surface 1c, the portion where the operation panel 72 is provided and the portion where the winged needle 11 is pulled out are exposed from the shielding member 62.

According to the arrangement of the shielding member as shown in FIGS. 4 to 7, when the administer is located near the front side of the side surface 1e or the side surface 1f of the radiopharmaceutical administration device 1 in order to administer the radiopharmaceutical to the subject. The shielding member 63 or the shielding member 64 can shield the radiation directed from the radioactive drug administration device 1 to the administrator. Further, when the administrator is located near the front surface 1a of the radiopharmaceutical administration device 1 and a part of the body is located near the front side of the upper surface 1c in order to operate the operation panel 72, the shielding member 61 and the shielding member 62 are used. The radiation from the radioactive drug administration device 1 to the admin can be shielded. Further, in the internal space of the radioactive drug administration device 1, the radiation in the upper region is large, while the radiation in the lower region is small. Therefore, by covering only the upper region of the radioactive drug administration device 1 with the shielding members 61, 63, 64, the shielding performance for only the necessary portion can be improved.

Next, the action / effect of the radioactive drug administration system 100 according to the present embodiment will be described.

The radioactive drug administration system 100 according to the present embodiment is arranged so as to cover the periphery of the radioactive drug administration device 1, and has a frame portion 50 to which shielding members 61, 62, 63, 64, 65 for shielding radiation can be attached. Shielding members 61, 62, 63, 64, 65 attached to the frame portion 50 are provided. In such a configuration, the shielding function against radiation can be enhanced only by attaching the shielding members 61, 62, 63, 64, 65 to the frame portion 50. Further, since it is not necessary to change the shielding wall 2 itself of the radioactive drug administration device 1, the shielding function can be enhanced without filing a regulatory application. As described above, the shielding function of the radioactive drug administration system 100 can be easily enhanced.

Further, the frame portion 50 can be attached with shielding members 61, 62, 63, 64, 65 at any position. In this case, it is possible to enhance the shielding function of the required portion according to the safety standard and the usage condition of the facility of the radioactive drug administration system 100. For example, when the layout of the room in which the radioactive drug administration system 100 is arranged is changed and the required radiation shielding mode is changed, the frame portion of the shielding member is not changed without changing the structure of the shielding wall 2. The layout can be easily changed by simply changing the mounting location for the 50.

Further, the frame portion 50 is configured so as to be close to and separated from the radioactive drug administration device 1. In this case, the shielding members 61, 62, 63, 64, 65 can be attached to the frame portion 50 in a state where the frame portion 50 is separated from the radioactive drug administration device 1.

Further, the frame portion 50 includes wheels 59. In this case, the frame portion 50 can be brought close to and separated from the radioactive drug administration device 1 with a simple configuration.

The present invention can be carried out in various forms having various changes and improvements based on the knowledge of those skilled in the art, including the above-mentioned embodiment. It is also possible to construct a modified example of the embodiment by utilizing the technical matters described in the above-described embodiment. The configurations of the respective embodiments may be combined and used as appropriate.

For example, the configuration of the frame portion is not limited to the above-described embodiment. For example, although two members 57 and 58 have been adopted as members extending in the vertical direction, three or more members may be provided. For example, members extending in the vertical direction may be provided at each of the four corners of the upper and lower frames.

Further, although the radiopharmaceutical administration system includes one frame portion, it may have a plurality of frame portions. For example, the entire circumference of the radiopharmaceutical administration device may be surrounded by two frame portions from the front-rear direction.

Further, although the frame portion is configured to be close to and separated from the radioactive drug administration device by providing the wheel portion, the frame portion may be configured to be close to and separated from the radioactive drug administration device by another mechanism. For example, a slide portion may be provided on the floor portion so as to reciprocate the frame portion.

1 ... Radioactive drug administration device, 50 ... Frame part, 59 ... Wheels, 61, 62, 63, 64, 65 ... Shielding member.

Claims (3)

A radiopharmaceutical administration device for accommodating a radiopharmaceutical inside a shielding wall and administering the radiopharmaceutical, and a radiopharmaceutical administration device.
A frame portion that is arranged so as to surround the outside of the radioactive drug administration device and to which a shielding member that shields radiation can be attached.
The shielding member attached to the frame portion is provided .
The frame portion is a radioactive drug administration system configured so as to be close to and separated from the radioactive drug administration device. The radioactive drug administration system according to claim 1, wherein the shielding member can be attached to the frame portion at an arbitrary position. The radioactive drug administration system according to claim 1 , wherein the frame portion includes wheels.

Images